Premium
PDF
PDF
Download Download
EXAMS
Foundations | Questions & Answers (Verified Answers) With Rationales
( Update)
This Document Contains:
190 Questions with Correct, Detailed and Verified Answers
2026/2027 Actual Exam Testbank
Questions & Answers (Verified Answers) With Rationales
100% Guaranteed Pass
Complete A+ Guide
Page 1
,Question 1
A 65-year-old patient with chronic kidney disease (stage 4, eGFR 25 mL/min) and type 2 diabetes
is prescribed metformin. Which of the following best describes the primary concern with this
prescription?
A) Increased risk of lactic acidosis due to impaired renal clearance
B) Reduced efficacy of metformin due to uremic toxin interference
C) Increased risk of hypoglycemia due to altered insulin sensitivity
D) Accelerated renal decline due to metformin-induced nephrotoxicity
Answer: A) Increased risk of lactic acidosis due to impaired renal clearance
Explanation: Metformin is contraindicated in advanced CKD (eGFR <30 mL/min) because it
accumulates and increases the risk of lactic acidosis. Option B is not a primary concern;
uremic toxins do not significantly interfere. Option C is less specific; hypoglycemia risk
is lower than lactic acidosis. Option D is incorrect; metformin is not directly
nephrotoxic.
Question 2
A researcher is studying a novel drug that inhibits the efflux transporter P-glycoprotein (P-gp) in
the intestinal epithelium. Which of the following is the most likely effect on the pharmacokinetics
of coadministered substrates of CYP3A4?
A) Decreased oral bioavailability and increased clearance
B) Increased oral bioavailability and decreased clearance
C) No change in bioavailability but increased volume of distribution
D) Decreased renal excretion and increased half-life
Answer: B) Increased oral bioavailability and decreased clearance
Explanation: P-gp inhibition reduces efflux of substrates back into the gut lumen, increasing
absorption and oral bioavailability. Many P-gp substrates are also CYP3A4 substrates;
inhibition of P-gp can lead to higher concentrations, potentially overwhelming hepatic
metabolism and decreasing clearance. Option A is opposite. Option C is incorrect
because bioavailability changes. Option D is not a direct effect; renal excretion may not
be affected.
Page 2
,Question 3
Which of the following mechanisms best explains the development of resistance to imatinib in
chronic myeloid leukemia (CML)?
A) Overexpression of the drug target BCR-ABL due to gene amplification
B) Increased efflux of imatinib via upregulation of ABC transporters
C) Point mutations in the BCR-ABL kinase domain that reduce drug binding
D) Epigenetic silencing of pro-apoptotic genes leading to reduced cell death
Answer: C) Point mutations in the BCR-ABL kinase domain that reduce drug binding
Explanation: The most common mechanism of resistance to imatinib is the acquisition of point
mutations in the BCR-ABL kinase domain (e.g., T315I) that prevent imatinib binding.
While options A and B can occur, they are less frequent. Option D is not a primary
mechanism for imatinib resistance.
Question 4
A patient with severe hepatic impairment (Child-Pugh class C) requires treatment with a drug that
undergoes extensive first-pass metabolism. Which dosage adjustment is most appropriate?
A) Increase the dose to compensate for reduced hepatic clearance
B) Reduce the dose and prolong the dosing interval
C) No adjustment needed; first-pass metabolism is extrahepatic
D) Administer the drug intravenously to bypass first-pass effect
Answer: B) Reduce the dose and prolong the dosing interval
Explanation: In severe hepatic impairment, first-pass metabolism is reduced, leading to higher
systemic levels. Therefore, the dose should be reduced and the interval prolonged to
avoid toxicity. Option A would increase toxicity. Option C is false; first-pass
metabolism is primarily hepatic. Option D may be considered but does not address the
need for dose reduction if the drug is given orally.
Question 5
Which of the following statements best describes the role of the microbiome in drug metabolism?
A) Gut bacteria primarily conjugate drugs with glucuronic acid, enhancing excretion
B) Microbial enzymes can reactivate drugs that have been inactivated by the liver
C) The microbiome has minimal impact on drug pharmacokinetics in humans
D) Antibiotics consistently increase the bioavailability of all oral drugs
Answer: B) Microbial enzymes can reactivate drugs that have been inactivated by the liver
Explanation: Gut bacteria can perform reactions such as deconjugation, which reactivate drugs
previously conjugated in the liver (e.g., irinotecan). Option A is incorrect; conjugation is
primarily hepatic. Option C is false; the microbiome significantly affects drug
metabolism. Option D is incorrect; effects vary widely.
Page 3
, Question 6
A patient is on warfarin therapy and is prescribed a course of levofloxacin. Which of the following
best describes the potential interaction?
A) Levofloxacin induces CYP2C9, decreasing warfarin efficacy
B) Levofloxacin inhibits CYP2C9, increasing warfarin effect and bleeding risk
C) Levofloxacin displaces warfarin from plasma proteins, causing transient increase in INR
D) Levofloxacin has no significant interaction with warfarin
Answer: B) Levofloxacin inhibits CYP2C9, increasing warfarin effect and bleeding risk
Explanation: Levofloxacin inhibits CYP2C9, the enzyme that metabolizes the more potent
S-warfarin, leading to increased anticoagulant effect and bleeding risk. Option A is
opposite. Option C is not the primary mechanism. Option D is incorrect; a significant
interaction exists.
Question 7
Which of the following best explains why angiotensin-converting enzyme inhibitors (ACEIs) are
preferred over angiotensin receptor blockers (ARBs) in patients with proteinuric chronic kidney
disease?
A) ACEIs more effectively reduce intraglomerular pressure by dilating efferent arterioles
B) ACEIs increase bradykinin levels, which provide additional renoprotective effects
C) ARBs have a higher risk of hyperkalemia compared to ACEIs
D) ACEIs are more effective at lowering blood pressure than ARBs
Answer: B) ACEIs increase bradykinin levels, which provide additional renoprotective effects
Explanation: ACEIs inhibit the breakdown of bradykinin, which has antiproliferative and antifibrotic
effects, providing additional renoprotection beyond blood pressure reduction. ARBs do
not affect bradykinin. Option A is not accurate; both dilate efferent arterioles. Option C
is incorrect; ARBs also cause hyperkalemia. Option D is not a consistent difference.
Page 4
Download Download
EXAMS
Foundations | Questions & Answers (Verified Answers) With Rationales
( Update)
This Document Contains:
190 Questions with Correct, Detailed and Verified Answers
2026/2027 Actual Exam Testbank
Questions & Answers (Verified Answers) With Rationales
100% Guaranteed Pass
Complete A+ Guide
Page 1
,Question 1
A 65-year-old patient with chronic kidney disease (stage 4, eGFR 25 mL/min) and type 2 diabetes
is prescribed metformin. Which of the following best describes the primary concern with this
prescription?
A) Increased risk of lactic acidosis due to impaired renal clearance
B) Reduced efficacy of metformin due to uremic toxin interference
C) Increased risk of hypoglycemia due to altered insulin sensitivity
D) Accelerated renal decline due to metformin-induced nephrotoxicity
Answer: A) Increased risk of lactic acidosis due to impaired renal clearance
Explanation: Metformin is contraindicated in advanced CKD (eGFR <30 mL/min) because it
accumulates and increases the risk of lactic acidosis. Option B is not a primary concern;
uremic toxins do not significantly interfere. Option C is less specific; hypoglycemia risk
is lower than lactic acidosis. Option D is incorrect; metformin is not directly
nephrotoxic.
Question 2
A researcher is studying a novel drug that inhibits the efflux transporter P-glycoprotein (P-gp) in
the intestinal epithelium. Which of the following is the most likely effect on the pharmacokinetics
of coadministered substrates of CYP3A4?
A) Decreased oral bioavailability and increased clearance
B) Increased oral bioavailability and decreased clearance
C) No change in bioavailability but increased volume of distribution
D) Decreased renal excretion and increased half-life
Answer: B) Increased oral bioavailability and decreased clearance
Explanation: P-gp inhibition reduces efflux of substrates back into the gut lumen, increasing
absorption and oral bioavailability. Many P-gp substrates are also CYP3A4 substrates;
inhibition of P-gp can lead to higher concentrations, potentially overwhelming hepatic
metabolism and decreasing clearance. Option A is opposite. Option C is incorrect
because bioavailability changes. Option D is not a direct effect; renal excretion may not
be affected.
Page 2
,Question 3
Which of the following mechanisms best explains the development of resistance to imatinib in
chronic myeloid leukemia (CML)?
A) Overexpression of the drug target BCR-ABL due to gene amplification
B) Increased efflux of imatinib via upregulation of ABC transporters
C) Point mutations in the BCR-ABL kinase domain that reduce drug binding
D) Epigenetic silencing of pro-apoptotic genes leading to reduced cell death
Answer: C) Point mutations in the BCR-ABL kinase domain that reduce drug binding
Explanation: The most common mechanism of resistance to imatinib is the acquisition of point
mutations in the BCR-ABL kinase domain (e.g., T315I) that prevent imatinib binding.
While options A and B can occur, they are less frequent. Option D is not a primary
mechanism for imatinib resistance.
Question 4
A patient with severe hepatic impairment (Child-Pugh class C) requires treatment with a drug that
undergoes extensive first-pass metabolism. Which dosage adjustment is most appropriate?
A) Increase the dose to compensate for reduced hepatic clearance
B) Reduce the dose and prolong the dosing interval
C) No adjustment needed; first-pass metabolism is extrahepatic
D) Administer the drug intravenously to bypass first-pass effect
Answer: B) Reduce the dose and prolong the dosing interval
Explanation: In severe hepatic impairment, first-pass metabolism is reduced, leading to higher
systemic levels. Therefore, the dose should be reduced and the interval prolonged to
avoid toxicity. Option A would increase toxicity. Option C is false; first-pass
metabolism is primarily hepatic. Option D may be considered but does not address the
need for dose reduction if the drug is given orally.
Question 5
Which of the following statements best describes the role of the microbiome in drug metabolism?
A) Gut bacteria primarily conjugate drugs with glucuronic acid, enhancing excretion
B) Microbial enzymes can reactivate drugs that have been inactivated by the liver
C) The microbiome has minimal impact on drug pharmacokinetics in humans
D) Antibiotics consistently increase the bioavailability of all oral drugs
Answer: B) Microbial enzymes can reactivate drugs that have been inactivated by the liver
Explanation: Gut bacteria can perform reactions such as deconjugation, which reactivate drugs
previously conjugated in the liver (e.g., irinotecan). Option A is incorrect; conjugation is
primarily hepatic. Option C is false; the microbiome significantly affects drug
metabolism. Option D is incorrect; effects vary widely.
Page 3
, Question 6
A patient is on warfarin therapy and is prescribed a course of levofloxacin. Which of the following
best describes the potential interaction?
A) Levofloxacin induces CYP2C9, decreasing warfarin efficacy
B) Levofloxacin inhibits CYP2C9, increasing warfarin effect and bleeding risk
C) Levofloxacin displaces warfarin from plasma proteins, causing transient increase in INR
D) Levofloxacin has no significant interaction with warfarin
Answer: B) Levofloxacin inhibits CYP2C9, increasing warfarin effect and bleeding risk
Explanation: Levofloxacin inhibits CYP2C9, the enzyme that metabolizes the more potent
S-warfarin, leading to increased anticoagulant effect and bleeding risk. Option A is
opposite. Option C is not the primary mechanism. Option D is incorrect; a significant
interaction exists.
Question 7
Which of the following best explains why angiotensin-converting enzyme inhibitors (ACEIs) are
preferred over angiotensin receptor blockers (ARBs) in patients with proteinuric chronic kidney
disease?
A) ACEIs more effectively reduce intraglomerular pressure by dilating efferent arterioles
B) ACEIs increase bradykinin levels, which provide additional renoprotective effects
C) ARBs have a higher risk of hyperkalemia compared to ACEIs
D) ACEIs are more effective at lowering blood pressure than ARBs
Answer: B) ACEIs increase bradykinin levels, which provide additional renoprotective effects
Explanation: ACEIs inhibit the breakdown of bradykinin, which has antiproliferative and antifibrotic
effects, providing additional renoprotection beyond blood pressure reduction. ARBs do
not affect bradykinin. Option A is not accurate; both dilate efferent arterioles. Option C
is incorrect; ARBs also cause hyperkalemia. Option D is not a consistent difference.
Page 4
